MA34331B1 - Composés pyrazole comme inhibiteurs du récepteur sigma - Google Patents

Composés pyrazole comme inhibiteurs du récepteur sigma

Info

Publication number
MA34331B1
MA34331B1 MA35483A MA35483A MA34331B1 MA 34331 B1 MA34331 B1 MA 34331B1 MA 35483 A MA35483 A MA 35483A MA 35483 A MA35483 A MA 35483A MA 34331 B1 MA34331 B1 MA 34331B1
Authority
MA
Morocco
Prior art keywords
sigma receptor
inhibitors
pyrazole compounds
sigma
compounds
Prior art date
Application number
MA35483A
Other languages
English (en)
Inventor
Lopez Monica Garcia
Jover Antoni Torrens
Fernandez Jose Luis Diaz
Moure Ana Maria Caamano
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA34331B1 publication Critical patent/MA34331B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE GÉNÉRALE (I) AYANT UNE ACTIVITÉ PHARMACOLOGIQUE VIS-À-VIS DU RÉCEPTEUR SIGMA, DES PROCÉDÉS DE PRÉPARATION DE TELS COMPOSÉS, DES COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT ET LEUR UTILISATION POUR LE TRAITEMENT OU LA PROPHYLAXIE D'UNE MALADIE DANS LAQUELLE LE RÉCEPTEUR SIGMA EST MIS EN JEU.
MA35483A 2010-05-27 2011-05-26 Composés pyrazole comme inhibiteurs du récepteur sigma MA34331B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382148A EP2395003A1 (fr) 2010-05-27 2010-05-27 Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma
PCT/EP2011/058633 WO2011147910A1 (fr) 2010-05-27 2011-05-26 Composés pyrazole comme inhibiteurs du récepteur sigma

Publications (1)

Publication Number Publication Date
MA34331B1 true MA34331B1 (fr) 2013-06-01

Family

ID=42931975

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35483A MA34331B1 (fr) 2010-05-27 2011-05-26 Composés pyrazole comme inhibiteurs du récepteur sigma

Country Status (33)

Country Link
US (1) US9181195B2 (fr)
EP (2) EP2395003A1 (fr)
JP (2) JP5932779B2 (fr)
KR (1) KR101819680B1 (fr)
CN (1) CN103003267B (fr)
AR (1) AR081426A1 (fr)
AU (1) AU2011257208B2 (fr)
BR (1) BR112012030024B1 (fr)
CA (1) CA2800103C (fr)
CO (1) CO6640327A2 (fr)
CY (1) CY1118682T1 (fr)
DK (1) DK2576543T3 (fr)
EC (1) ECSP12012270A (fr)
ES (1) ES2616084T3 (fr)
HR (1) HRP20170361T1 (fr)
HU (1) HUE031755T2 (fr)
IL (1) IL223300A (fr)
LT (1) LT2576543T (fr)
MA (1) MA34331B1 (fr)
ME (1) ME02625B (fr)
MX (1) MX338226B (fr)
NZ (1) NZ603532A (fr)
PL (1) PL2576543T3 (fr)
PT (1) PT2576543T (fr)
RS (1) RS55750B1 (fr)
RU (1) RU2582338C2 (fr)
SG (1) SG185720A1 (fr)
SI (1) SI2576543T1 (fr)
TN (1) TN2012000534A1 (fr)
TW (1) TWI507195B (fr)
UA (1) UA112160C2 (fr)
WO (1) WO2011147910A1 (fr)
ZA (1) ZA201208799B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2395003A1 (fr) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2682395A1 (fr) * 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Dérivés d'imidazo[2,1-b]thiazole, leur préparation et leur utilisation comme médicaments
EP3082782A1 (fr) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
KR20160098506A (ko) * 2013-12-20 2016-08-18 라보라토리오스 델 드라. 에스테브.에스.에이. 통증에 대한 다양한 활성을 갖는 피페라진 유도체
CN103896835A (zh) * 2014-04-20 2014-07-02 武汉珈瑜科技有限公司 喹啉酮类衍生物及其应用
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
WO2016096127A1 (fr) * 2014-12-15 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Composés méthyl-1h-pyrazole-alkylamines ayant une activité multimodale contre la douleur
JP6761413B2 (ja) 2015-06-11 2020-09-23 富士フイルム富山化学株式会社 シグマ受容体結合剤
AR105888A1 (es) * 2015-09-02 2017-11-22 Esteve Labor Dr Sales de 1-(4-(2-((1-(3,4-difluorofenil)1h-pirazol-3-il)metoxi)etil)piperazin-1-il)etanona
EP3336085A1 (fr) 2016-12-15 2018-06-20 Laboratorios del Dr. Esteve S.A. Procédé et intermédiaire pour la préparation de 1- (4- (2- ((1- (3,4-difluorophényl) -1h-pyrazole-3-yl) méthoxy) éthyl) pipérazine-1-yl) éthanone
CN111793032B (zh) * 2019-04-08 2021-11-19 四川省中医药科学院 一类吡唑啉酮类化合物及其制备方法和用途
CN113929649B (zh) * 2021-11-22 2022-11-01 河北化工医药职业技术学院 一种科里内酯衍生物的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2301250A1 (fr) 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
FR2460299A1 (fr) 1979-07-05 1981-01-23 Bellon Labor Sa Roger Nouveaux derives du pyrazole et leur application therapeutique
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
WO1991009594A1 (fr) 1989-12-28 1991-07-11 Virginia Commonwealth University Ligands de recepteur sigma et leur emploi
EP0445974A3 (en) 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5240925A (en) 1991-08-26 1993-08-31 Rohm And Haas Company Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2002092573A2 (fr) 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Inhibiteurs de src et autres proteine kinases
WO2002102387A1 (fr) 2001-06-18 2002-12-27 H. Lundbeck A/S Traitement de la douleur neuropathique
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
JP2004196678A (ja) * 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
AU2005276590B2 (en) 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
DK1781618T3 (da) * 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
CA2613522A1 (fr) * 2005-06-27 2007-01-04 Exelixis, Inc. Regulateurs de lxr de type imidazole
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
WO2007079086A1 (fr) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Composés imidazo cycliques substitués par des groupements pyrazoloalkyle et méthodes
EP1829873A1 (fr) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Dérivés du pyrazole antagonistes des récepteurs sigma
EP1829866A1 (fr) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs des récepteurs sigma
EP1829867A1 (fr) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Composés d'imidazole ayant une acitivité pharmaceutique vis-à-vis le recepteur sigma
WO2007108517A1 (fr) 2006-03-22 2007-09-27 Matsushita Electric Industrial Co., Ltd. Dispositif d'examen sanguin
EP1921071A1 (fr) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazoles en tant qu'inhibiteurs du récepteur sigma
KR100868353B1 (ko) * 2007-03-08 2008-11-12 한국화학연구원 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
EP2113501A1 (fr) 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. Pyrazoles de 5-Methyl-1-(naphthalen-2-YL)-1H- utiles en tant qu'inhibiteurs de récepteur sigma
EP2395003A1 (fr) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma

Also Published As

Publication number Publication date
LT2576543T (lt) 2017-02-10
EP2395003A1 (fr) 2011-12-14
CO6640327A2 (es) 2013-03-22
RU2582338C2 (ru) 2016-04-27
CA2800103A1 (fr) 2011-12-01
PT2576543T (pt) 2017-03-16
ECSP12012270A (es) 2012-11-30
SI2576543T1 (sl) 2017-03-31
JP5932779B2 (ja) 2016-06-08
CA2800103C (fr) 2018-07-31
ME02625B (fr) 2017-06-20
ES2616084T3 (es) 2017-06-09
ZA201208799B (en) 2014-01-29
IL223300A0 (en) 2013-02-03
BR112012030024B1 (pt) 2021-01-12
EP2576543B1 (fr) 2016-12-21
BR112012030024A2 (pt) 2016-08-02
RS55750B1 (sr) 2017-07-31
UA112160C2 (uk) 2016-08-10
DK2576543T3 (en) 2017-03-06
CN103003267A (zh) 2013-03-27
EP2576543A1 (fr) 2013-04-10
HUE031755T2 (hu) 2017-07-28
CY1118682T1 (el) 2017-07-12
TWI507195B (zh) 2015-11-11
AU2011257208A1 (en) 2012-11-29
JP2013528171A (ja) 2013-07-08
PL2576543T3 (pl) 2017-05-31
KR20130119854A (ko) 2013-11-01
US20130158029A1 (en) 2013-06-20
TW201208679A (en) 2012-03-01
IL223300A (en) 2016-07-31
MX338226B (es) 2016-04-08
WO2011147910A1 (fr) 2011-12-01
RU2012156925A (ru) 2014-07-10
KR101819680B1 (ko) 2018-01-17
JP2016065092A (ja) 2016-04-28
NZ603532A (en) 2014-07-25
SG185720A1 (en) 2012-12-28
HRP20170361T1 (hr) 2017-04-21
TN2012000534A1 (en) 2014-04-01
AR081426A1 (es) 2012-08-29
AU2011257208B2 (en) 2016-05-19
US9181195B2 (en) 2015-11-10
CN103003267B (zh) 2018-05-25
MX2012013667A (es) 2013-02-11

Similar Documents

Publication Publication Date Title
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
MA30514B1 (fr) Nouveaux composes.
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA41014B1 (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
MA34308B1 (fr) Triazolopyridines substituées
MA41179A (fr) Composés inhibiteurs de parg
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2